Camlipixant (gefapixant)
Refractory Chronic Cough
Regulatory ReviewUnder Review
Key Facts
About GSK plc
GSK is a London-headquartered, publicly traded biopharma giant with a market cap of ~$109B, focused exclusively on pharmaceuticals and vaccines following the 2022 spin-off of its consumer health division. Its mission is to positively impact the health of 2.5 billion people by 2030 through disciplined R&D in four core therapeutic areas: Respiratory/Immunology, Oncology, HIV, and Infectious Diseases. The company leverages advanced genetic research, AI, and platform technologies to drive a pipeline of approximately 130 programs, aiming for sustained growth from both its established portfolio and novel pipeline assets.
View full company profileOther Refractory Chronic Cough Drugs
| Drug | Company | Phase |
|---|---|---|
| EX937 | Exxel Pharma | Pre-clinical |